Cas:849811-78-5 sodium,(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate manufacturer & supplier

We serve Chemical Name:sodium,(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate CAS:849811-78-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

sodium,(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate

Chemical Name:sodium,(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate
CAS.NO:849811-78-5
Synonyms:sodium,(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate
Molecular Formula:C26H26FNO4
Molecular Weight:435.48700
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:79.65000
Exact Mass:435.18500
LogP:4.60650

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like sodium,(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,sodium,(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,sodium,(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate Use and application,sodium,(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate technical grade,usp/ep/jp grade.


Related News: Green Valley said it would launch the drug ��very soon�� in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug. sodium,(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate manufacturer It also said it would bar South Koreans from visiting China as tourists. sodium,(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate supplier If the results from that trial are positive, the company might apply to the U.S. Food and Drug Administration for the same accelerated approval pathway recently used to bring the controversial Alzheimer’s drug aducanumab to market, Novak said. sodium,(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate vendor A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting. sodium,(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate factory However, pharmaceutical intermediates are subdivided into primary intermediates and advanced intermediates. Because primary intermediate suppliers can only provide simple intermediate production, they are at the front end of the industrial chain. The pressure of competition and price is the greatest. The price fluctuations of basic chemical raw materials have a greater impact on them.